ArticleHereditas2025
Single-cell transcriptomic analysis of peripheral blood mononuclear cells reveals key immune responses in ST-segment elevation myocardial infarction.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundInflammation plays a crucial role in the pathogenesis of ST-segment elevation myocardial infarction (STEMI). However, the precise immunological mechanisms remain incompletely understood. Single-cell RNA sequencing (scRNA-seq) provides a powerful approach to dissect immune cell heterogeneity and dynamic changes at single-cell resolution.
methodsPeripheral blood mononuclear cells (PBMCs) were collected from 7 STEMI patients (within 6h after primary percutaneous coronary intervention) and 3 healthy controls. Single-cell suspensions were prepared and subjected to scRNA-seq using the 10x Genomics Chromium platform and Illumina NovaSeq 6000. Data were processed using Cell Ranger and analyzed with Seurat for quality control, clustering, and annotation. Differentially expressed genes (DEGs) were identified and analyzed through Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), gene set variation analysis (GSVA), and gene set enrichment analysis (GSEA). Cell-cell communication was inferred using CellChat. And protein–protein interaction (PPI) network analysis was performed via STRING and Cytoscape. Key genes were validated using quantitative real-time PCR (qRT-PCR).
resultsA total of 71,288 PBMCs were analyzed. Significant differences in immune cell composition were observed between groups, especially in monocytes and T cells. Monocytes were divided into 10 subclusters; subclusters 0, 1, and 6 showed marked expansion and were functionally associated with inflammation, antigen presentation, and cytokine regulation. PPI network analysis identified JUN as a key hub gene, which was confirmed by qRT-PCR. T cells were divided into 7 subtypes, and GSEA revealed enrichment of IL-2/STAT5 and TNF-α/NF-κB signaling in STEMI. CD69 and ICOS were significantly upregulated in T cells. CellChat analysis revealed enhanced intercellular communication in STEMI, with the CXCL signaling pathway (notably PF4–CXCR3 interaction) being highly upregulated.
conclusionsThis study reveals key inflammatory and immune characteristics of PBMCs in STEMI patients. JUN and the CXCL signaling axis represent potential targets for immunomodulatory therapy in acute myocardial infarction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.